Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

ORUKA Aktie

>ORUKA Aktienkurs

10.15 EUR (Tradegate)

Ask: 10.3 EUR / 194 Stück

Bid: 10 EUR / 200 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

ORUKA Aktie über LYNX handeln

Intraday

1 Jahr

>ORUKA Performance

1 Woche: -6,9%

1 Monat: +5,2%

3 Monate: -11,0%

6 Monate: -46,9%

1 Jahr: 0%

laufendes Jahr: -43,6%

>ORUKA Aktie

Name:

ORUKA THERAPEUTICS INC.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6876041087 / A3DPH3

Symbol/ Ticker:

HQ1 (Frankfurt) / ORKA (NASDAQ)

Kürzel:

FRA:HQ1, ETR:HQ1, HQ1:GR, NASDAQ:ORKA

Index:

Webseite:

https://orukatx.com/

Marktkapitalisierung:

405.43 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

Schulden:

0.82 Mio. EUR

Liquide Mittel:

301.4 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / - / -

Gewinnm./ Eigenkapitalr.:

- / -

Dividende je Aktie:

17.406 EUR

Dividendenrendite/ -schätzung:

162.7% / -

Div. Historie:

29.08.24 - 17.40648€

Insiderhandel:

Suchwörter:

ORUKA

Letzte Datenerhebung:

24.06.25

>ORUKA Eigentümer

Aktien: 37.44 Mio. St.

f.h. Aktien: 22.63 Mio. St.

Insider Eigner: 3.25%

Instit. Eigner: 86.54%

Leerverk. Aktien: -

>ORUKA Peer Group

ALIGOS

ASPEN PHARMACARE ADR

BRAINSTORM CELL

EVOKE PHARMA

GENENTA

HYPERA

PERSPECTIVE THERAPEUTICS

PURPLE BIOTECH

SONOMA PHARMACEUTICALS

SYSMEX ADR

>ORUKA Chart & Kurs - NASDAQ

>ORUKA News

21.05.25 - 13:03	Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire EN)
	MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:...

20.05.25 - 22:03	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody (GlobeNewswire EN)
	Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025...

14.05.25 - 22:18	Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Continued operational excellence leading to acceleration of multiple timelines:...

07.03.25 - 14:33	Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting (GlobeNewswire EN)
	Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year...

06.03.25 - 22:12	Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 105043 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-11...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 1015803 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-14...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 6257 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-10...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 173869 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-13...

28.02.25 - 05:01	Insiderhandel: Insider kauft Aktien von Oruka Therapeutics im Wert von 106396 USD (Insiderkauf)
	Venrock Healthcare Capital Partners III, L.p. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2025-02-12...

19.02.25 - 13:03	Oruka Therapeutics to Present at Multiple March Investor Conferences (GlobeNewswire EN)
	MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:...

19.12.24 - 13:03	Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody (GlobeNewswire EN)
	Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025...

18.12.24 - 13:03

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire EN)

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka's addition will become effective prior to market open on Monday, December 23rd, 2024....

14.11.24 - 19:27	Oruka Therapeutics files to sell 8.72M shares of common stock for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.24 - 00:03	Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.24 - 22:30	Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points...

04.11.24 - 13:03	Oruka Therapeutics to Present at Multiple November Investor Conferences (GlobeNewswire EN)
	MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:...

27.09.24 - 14:03	XFRA : HQ1: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN ORUKA THERAPEUTICS INC. HQ1 US6876041087 AB/FROM ONWARDS 27.09.2024 13:46 CET...

03.09.24 - 08:25	XFRA : HQ1: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ORUKA THERAPEUTICS INC. HQ1 US6876041087 BAW/UFN...

03.09.24 - 08:15	XFRA : INSTRUMENT_SUSPENSION - US6876041087 (XETRA)
	Instrument ID [20809920] (HQ1 - US6876041087) suspended...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram